Good Quality Diabetes Treatment Linagliptin CAS 668270-12-0

MOQ
1kg
Shipping Area
Worldwide/All Countries
Assay
99%
MW
472.54
Melting Point
202ºC
CAS
668270-12-0
Storage
Keep in Cool and Dry Place
Test Method
HPLC
Delivery
Express 5-7 Days Arrive
Shelf Life
2 Years
Appearance
White Powder
Transport Package
Foil Bag
Specification
99%
Trademark
Xi′an Frazer Biotech Co., Ltd.
Origin
China
Production Capacity
200kg Per Month
Reference Price
Please contact us for quote
Contact Us

Product Description

Good Quality Diabetes Treatment Linagliptin CAS 668270-12-0
Good Quality Diabetes Treatment Linagliptin CAS 668270-12-0
Good Quality Diabetes Treatment Linagliptin CAS 668270-12-0
Specification of Analysis
items Specifications Results
Appearance

White or off-white crystalline

powder

Conforms
HPLC

The retention time of the major peaking

the chromatogram of the sample corresponds

to that exhibited by the working standard

Conforms
Loss on drying No more than 1.0% 0.40%
Residue on Ignition No more than 0.1% 0.02%
Heavy Metals No more than 20ppm <10ppm
Related substances Total impurities no more than 1.0% 0.50%
  Single impurity no more than 0.5% Conforms
Residual solvents Eth yl ac etate No more than 0.1% Conforms
  Ethanol No more than 0.1% Conforms
Purity No less than 99.0% 99.50%

Description

Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for treatment of type II diabetes.

Linagliptin was approved by the U.S. Food and Drug Administration (FDA) on 2 May 2011 for treatment of type II diabetes. 

Application

Linagliptin  is a kind of dipeptide peptidase 4 (DPP - 4) inhibitors used as dietary and exercise in type 2 diabetes in adult auxiliary treatment to improve blood sugar control.

Linagliptin is used with a proper diet and exercise program and possibly with othermedications to control high blood sugar. It is used by people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs. Proper control of diabetes may also lessen your risk of a heart attack or stroke.

Functions

1. Incretin (Incretin) has the role of intestinal promoting ins ulin B cells to secrete ins ulin, mainly including glucose-dependent ins ulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). DDP-4 is a serine protease located on the cell surface, which is widely found in plasma and in vivo tissues (such as kidney, liver, small intestine villi, endothelial cells, etc.). Rilalitine is a selective DPP-4 inhibitor that inhibits the activity of the enzyme by reversibly binding to DPP-4, delays GLP-1 degradation, enhances GLP-1 activity, and stimulates glucose-dependent Ins ulin secretion, and reduce circulating levels of glucagon, thereby regulating blood glucose levels in patients with type 2 diabetes.

2. Compared with other DPP-4 inhibitors, the main advantages of liradetine is: with excellent renal safety, and can effectively reduce glycosylated hemoglobin. Lilardine mainly in the form of excretion of fecal excretion, the oral administration, the amount of renal excretion is only 5% of the dose, even if the intravenous administration, and only 30.8% of the excretion by the kidney, so the patient did not need treatment Regularly check the liver, kidney function and dose adjustment, all patients can be a unified fixed dose, easy to prescribe.

 

Pharmaceutical Intermediate

LEGALIS.IT, 2023